CN107075480A - γδT细胞及其用途 - Google Patents

γδT细胞及其用途 Download PDF

Info

Publication number
CN107075480A
CN107075480A CN201580037383.2A CN201580037383A CN107075480A CN 107075480 A CN107075480 A CN 107075480A CN 201580037383 A CN201580037383 A CN 201580037383A CN 107075480 A CN107075480 A CN 107075480A
Authority
CN
China
Prior art keywords
cells
gamma delta
subject
cell
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580037383.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·利克
A·汉尼根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tc Biological Pharmaceutical Co Ltd
Original Assignee
Tc Biological Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201412175A external-priority patent/GB201412175D0/en
Priority claimed from GB201415379A external-priority patent/GB201415379D0/en
Priority claimed from GBGB1506423.1A external-priority patent/GB201506423D0/en
Application filed by Tc Biological Pharmaceutical Co Ltd filed Critical Tc Biological Pharmaceutical Co Ltd
Publication of CN107075480A publication Critical patent/CN107075480A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/43—Protozoan antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580037383.2A 2014-07-09 2015-07-08 γδT细胞及其用途 Pending CN107075480A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1412175.0 2014-07-09
GB201412175A GB201412175D0 (en) 2014-07-09 2014-07-09 Gamma T cells and uses thereof
GB1415379.5 2014-08-29
GB201415379A GB201415379D0 (en) 2014-08-29 2014-08-29 Gamma T cells and uses thereof
GB1506423.1 2015-04-15
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof

Publications (1)

Publication Number Publication Date
CN107075480A true CN107075480A (zh) 2017-08-18

Family

ID=53776892

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580037383.2A Pending CN107075480A (zh) 2014-07-09 2015-07-08 γδT细胞及其用途

Country Status (12)

Country Link
US (2) US20170196910A1 (cg-RX-API-DMAC7.html)
EP (1) EP3167050A1 (cg-RX-API-DMAC7.html)
JP (3) JP2017524031A (cg-RX-API-DMAC7.html)
KR (1) KR20170045205A (cg-RX-API-DMAC7.html)
CN (1) CN107075480A (cg-RX-API-DMAC7.html)
AU (1) AU2015287456A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017000464A2 (cg-RX-API-DMAC7.html)
CA (1) CA2954546A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790010A1 (cg-RX-API-DMAC7.html)
IL (1) IL249970B (cg-RX-API-DMAC7.html)
SG (1) SG11201700134PA (cg-RX-API-DMAC7.html)
WO (1) WO2016005752A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555785A (zh) * 2019-10-17 2022-05-27 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US10532064B2 (en) * 2014-08-12 2020-01-14 The University Of Hong Kong Biophosphonate compounds and gamma delta T cell-mediated therapy for treating epstein-barr virus-associated disorders
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CA3032304A1 (en) * 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
WO2018055191A1 (en) * 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
WO2020065584A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
AU2019354395A1 (en) 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
EA202190926A1 (ru) 2018-10-01 2021-06-25 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
EP4434541A3 (en) 2019-01-23 2025-02-26 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
AU2023220748A1 (en) 2022-02-16 2024-07-25 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031641A (zh) * 2004-08-19 2007-09-05 伯哈德·莫瑟 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144339A0 (en) * 1999-01-28 2002-05-23 Palmetto Health Alliance A cell line containing gamma delta lymphocytes and pharmaceutical compositions containing the same
AU2001248162B2 (en) * 2000-04-03 2007-02-01 Hemosol Lp. Production of TcR gamma delta T cells
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
ATE476497T1 (de) * 2004-08-19 2010-08-15 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
EP1930414B1 (en) 2005-09-08 2012-07-18 Medinet Co., Ltd. Method for activation treatment of antigen-presenting cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031641A (zh) * 2004-08-19 2007-09-05 伯哈德·莫瑟 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
石远凯: "《中国肿瘤内科进展，中国肿瘤医师教育》", 30 June 2013, 中国协和医科大学出版社 *
赵富玺等: "《医学免疫学》", 30 April 2013, 人民军医出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555785A (zh) * 2019-10-17 2022-05-27 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法

Also Published As

Publication number Publication date
EP3167050A1 (en) 2017-05-17
US20170196910A1 (en) 2017-07-13
KR20170045205A (ko) 2017-04-26
EA201790010A1 (ru) 2017-05-31
SG11201700134PA (en) 2017-02-27
CA2954546A1 (en) 2016-01-14
AU2015287456A1 (en) 2017-02-02
IL249970B (en) 2019-11-28
BR112017000464A2 (pt) 2017-11-07
WO2016005752A1 (en) 2016-01-14
JP2017524031A (ja) 2017-08-24
US20210030794A1 (en) 2021-02-04
IL249970A0 (en) 2017-03-30
JP2020172522A (ja) 2020-10-22
JP2023123437A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
US20210030794A1 (en) Gamma delta t cells and uses thereof
JP6995624B2 (ja) 修正ガンマデルタｔ細胞およびその使用
JP7244461B2 (ja) 養子細胞療法のための改良型細胞培養方法
Wu et al. Human γδT-cell subsets and their involvement in tumor immunity
JP7258364B2 (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
Li et al. MART-1–specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro
US20130115617A1 (en) Methods of cell culture for adoptive cell therapy
US11473059B2 (en) Method for enrichment and expansion of virus antigen-specific T cells
KR20200104283A (ko) 적응 요법을 위한 항원-특이적 t 세포를 포함하는 세포 조성물
JP6525946B2 (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
AU2006288348A1 (en) Method for activation treatment of antigen-presenting cell
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
CA2873608C (en) Improved methods of cell culture for adoptive cell therapy
EA043265B1 (ru) Модифицированные гамма-дельта-t-клетки и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170818